CAJ Food Products marketed Biotta and Juice Performer juices with disease claims, making them unapproved new drugs, FDA says.
What happened
FDA reviewed the company’s Amazon storefronts in November–December 2021 and its linked websites; no inspection is mentioned. It found claims that the juices treat or prevent diseases including cancer, high blood pressure, COPD, diabetes, and gout. FDA said these claims make the products drugs and that they are not FDA-approved for those uses.
What FDA found
Website claims that the juices cure, mitigate, treat, or prevent diseases make them drugs.
section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)]The products are new drugs because they are not generally recognized as safe and effective for those uses, and FDA has not approved them.
sections 201(p), 301(d), and 505(a) of the Act [21 U.S.C. 321(p), 331(d), 355(a)]The products are misbranded because they lack adequate directions for a layperson to use them safely for their intended disease uses.
section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]; 21 CFR 201.5Selling these misbranded drugs in interstate commerce violates the Act.
section 301(a) of the Act [21 U.S.C. 331(a)]
What FDA wants
Within 15 working days of receipt, notify FDA in writing of the specific steps taken to correct the violations and prevent recurrence, with related documents. If corrections will take longer, explain why and give a completion date.
Who should pay attention
- juice and beverage brands that make health claims
- retailers and Amazon sellers of juice products
- companies whose websites describe foods as disease treatments
This is a summary. Read the original letter on fda.gov.